The effect of high DHA/EPA PUFA and ascorbic acid in the treatment of refractory epileptic patients

Study the expression of CCR2, PPAR-G and NF-?B in peripheral blood leukocytes, oxidative stress and seizure frequency in drug-resistant epileptic patients, after combination therapy with High DHA/EPA PUFA and Ascorbic acid

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240220061057N1

Enrollment

Registered

2024-04-29

Start date

2024-05-04

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seizure. Epilepsy and recurrent seizures

Interventions

Intervention 1: Intervention group : patients will be placed in two groups A and B after random allocation. 15 patients in intervention group A will receive routine anticonvulsant treatments, and in a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Epileptic patients who take at least two antiepileptic drugs but have had at least one seizure in the last 6 months. Patients are at least 18 years old Willingness to participate in the study

Exclusion criteria

Exclusion criteria: pregnancy chronic kidney disease history of MI or vascular interventions history of renal stone use of anticoagulants history of allergy to ascorbic acid or DHA/EPA PUFA history of familial or acquired dyslipidemia The patient unwillingness to continue the combined treatment

Design outcomes

Primary

Measure	Time frame
CCR2 gene expression level. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: Real-time q PCR method.;PPAR-G gene expression level. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: Real-time q PCR.;NF-kB gene expression level. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: Real-time q PCR.;Oxidative stress marker: MDA. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: by laboratory measurement (according to the protocol of the purchased kit).;Seizure frequency. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: questionnaire.	—

Measure

Time frame

CCR2 gene expression level. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: Real-time q PCR method.;PPAR-G gene expression level. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: Real-time q PCR.;NF-kB gene expression level. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: Real-time q PCR.;Oxidative stress marker: MDA. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: by laboratory measurement (according to the protocol of the purchased kit).;Seizure frequency. Timepoint: before the start of the intervention and after the first period (end of the first four months) and again after the second period (end of the second quarter). (The study is of cross-over type and in the second quarter, the place of intervention of the groups is moved). Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRezavan Parkalian

Ardabil University of Medical Sciences

parkalianrezvan@gmail.com+98 45 3324 8888

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026